Janux therapeutics announces closing of underwritten public offering of common stock and pre-funded warrants including full exercise of underwriters' option to purchase additional shares for total gross proceeds of $402.5 million

San diego--(business wire)---- $janx--janux therapeutics, inc. (nasdaq: janx) (janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its tumor activated t cell engager (tractr) and tumor activated immunomodulator (tracir) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of.
JANX Ratings Summary
JANX Quant Ranking